Ipilimumab, a fully human monoclonal antibody IgG1 that inhibits the interaction between CTLA-4 and its ligands, was approved by FDA in 2011 for the treatment of unresectable stage III/IV melanoma, owing to the improvements in clinical outcomes. The gene discussed is CTLA4; the disease is melanoma.